- Home
- ORKA vs XNCR Comparison
ORKA vs XNCR Comparison
Compare ORKA & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORKA
- XNCR
- Stock Information
- Founded
- ORKA 2004
- XNCR 1997
- Country
- ORKA United States
- XNCR United States
- Employees
- ORKA N/A
- XNCR N/A
- Industry
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- ORKA Health Care
- XNCR Health Care
- Exchange
- ORKA Nasdaq
- XNCR Nasdaq
- Market Cap
- ORKA 580.3M
- XNCR 547.8M
- IPO Year
- ORKA N/A
- XNCR 2013
- Fundamental
- Price
- ORKA $15.44
- XNCR $8.41
- Analyst Decision
- ORKA Strong Buy
- XNCR Buy
- Analyst Count
- ORKA 9
- XNCR 9
- Target Price
- ORKA $40.38
- XNCR $25.00
- AVG Volume (30 Days)
- ORKA 142.1K
- XNCR 718.6K
- Earning Date
- ORKA 08-11-2025
- XNCR 08-06-2025
- Dividend Yield
- ORKA N/A
- XNCR N/A
- EPS Growth
- ORKA N/A
- XNCR N/A
- EPS
- ORKA N/A
- XNCR N/A
- Revenue
- ORKA N/A
- XNCR $146,929,000.00
- Revenue This Year
- ORKA N/A
- XNCR N/A
- Revenue Next Year
- ORKA N/A
- XNCR $28.84
- P/E Ratio
- ORKA N/A
- XNCR N/A
- Revenue Growth
- ORKA N/A
- XNCR N/A
- 52 Week Low
- ORKA $5.49
- XNCR $6.92
- 52 Week High
- ORKA $52.32
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- ORKA 59.14
- XNCR 55.89
- Support Level
- ORKA $14.10
- XNCR $7.13
- Resistance Level
- ORKA $15.76
- XNCR $7.99
- Average True Range (ATR)
- ORKA 1.12
- XNCR 0.53
- MACD
- ORKA 0.04
- XNCR 0.06
- Stochastic Oscillator
- ORKA 83.71
- XNCR 94.90
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.